Baseline monocyte count predicts symptom improvement during intravenous ketamine therapy in treatment-resistant depression: a single-arm open-label observational study.
Frontiers in Psychiatry 2024 Bruno Pedraz-Petrozzi, Moritz Spangemacher, Anton Deicher et al. 6 citations
Neuroinflammatory processes in depression are associated with treatment resistance to conventional antidepressants. Ketamine is an effective new therapeutic option for treatment-resistant depression (TRD). Its well-established immunomodulatory properties are hypothesized to mediate its antidepressant effect. In this context, higher levels of inflammation may predict a better treatment response....
DOI: 10.3389/fpsyt.2024.1415505 (opens in new tab)
Full text (opens in new tab)
Treatment-resistant depression
Immunity
Inflammation
Monocyte
+7